Depletion of p185(erbB2), Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 1, 1997, Pages 60-64

  An, Won G ^a   Schnur, Rodney C ^b   Neckers, Len ^a   Blagosklonny, Mikhail V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cancer cells; Geldanamycin; Mutant p53; p185(erbB2); Raf 1

Indexed keywords

ANSAMYCIN DERIVATIVE; GELDANAMYCIN; ONCOPROTEIN; PROTEIN P53; RAF PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MACROCYCLIC LACTAM; PROTEIN SERINE THREONINE KINASE; QUINONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DELETION MUTANT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MUTATION; PRIORITY JOURNAL; CELL CULTURE; DOWN REGULATION; FEMALE;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; DOWN-REGULATION; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; QUINONES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030612135     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050626     Document Type: Article

References (28)

1. Bartek J, Iggo R, Gannon J, Lane DP (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893
2. Benchekroun MN, Schneider E, Safa AR, Townsend AJ, Sinha BK (1994) Mechanisms of resistance to unsamycin antibiotics in human breast cancer cell lines. Mol Pharmacol 46: 677
3. Blagosklonny MV, Neckers LM (1994) The role of Bcl-2 protein and autocrine growth factors in a human follicular lymphoma-derived B cell line. Eur Cytokine Netw 6: 21
4. Blagosklonny MV, Toretsky J, Neckers L (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11: 933
5. Blagosklonny MV, Toretskey J, Bohen S, Neckers LM (1996) Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 93: 8379
6. crbB2 binds to GRP94 in vivo. J Biol Chem 271: 4974
7. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) p53 gain of function mutations. Nat Genet 4: 42
8. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M (1994) Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145: 702
9. June CH, Fletcher MC, Ledbetter JA, Schieven GL, Siegel JN, Phillips AF, Samelson LE (1990) Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci USA 87: 7722
10. Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, Greene MI (1995) Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nature Med 1: 644
11. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827
12. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351: 453
13. Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K (1995) Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 6: 135
14. Magnuson NS, Beck T, Vahidi H, Hahn H, Smola U, Rapp UR (1994) The Raf-1 serine threonine protein kinase. Sermin Cancer Biol 5: 247
15. Mcllwrath AJ, Brunton VG, Brown R (1996) Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother Pharmacol 37: 423
16. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD. (1994) Cancer Res 54: 2724
17. Miller P, Schnur RC, Barbacci E, Moyer MP, Moyer JD (1994) Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem Biophys Res Commun 201: 1313
18. Milner J, Medcalf EA (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765
19. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705
20. Prendergast GC, Gibbs JB (1994) Ras regulatory interactions: novel targets for anti-cancer intervention? Bioessays 16: 187
21. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, DiOrio CI, Barbacci EG, Miller PE, Pollack VA, Savage DM, Sloan DE, Pustilnik JD, Moyer JD, Moyer MP (1995) erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis mechanism of action, and structure-activity relationships. J Med Chem 38: 3813
22. Schnur RC, Corman RJ, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, Miller PE, O'Brien AT, Morin MJ, Foster BA, Pollack VA, Savage DM, Sloan DE, Pustilnik LR, Moyer MP (1995) Inhibition of the oncogene product p185 erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38: 3806
23. Schulte TW, Blagosklonny MV, Ingui C, Neckers L (1995) Disruption of the Ruf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270: 24585
24. Sepehrnia B, Paz IB, Dasgupta G, Momand J (1996) Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 271: 15084
25. Srivastava S, Wang S, Tong YA, Hao ZM, Chang EH (1993) Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res 53: 4452
26. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324
27. Whitesell L, Shifrin SD, Schwab G, Neckers LM (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 52: 1721
28. Wiechen K, Dietel M (1995) c-erbB-2 anti-sense phosphorothioate oligonueleotides inhibit growth and serum-induced cell spreading of P185c-erbB2-overexpressing ovarian carcinoma cells. Int J Cancer 63: 604